Table 3.

Completeness of Reporting in 23 Categories for 323^a English-Language Publications of Novel Stem Cell Clinical Trials

Reporting Categoryb	Completely Reported n (% of Applicable Trials)	Partially Reported n (% of Applicable Trials)	Not Reported n (% of Applicable Trials)	Category Not Applicable n
Background
Background/rationale	310 (93.1)	12 (3.6)	1 (0.3)	0
Methods
Interventions	310 (93.1)	12 (3.6)	1 (0.3)	0
Trial design	275 (82.6)	27 (8.1)	21 (6.3)	0
Primary outcome	266 (79.9)	54 (16.2)	3 (0.9)	0
Statistical methods	253 (76.0)	16 (4.8)	54 (16.2)	0
Participant criteria	246 (73.9)	57 (17.1)	19 (5.7)	0
Secondary outcome	201 (63.8)	43 (13.6)	71 (22.5)	8
Trial phase	183 (55.0)	1 (0.3)	139 (41.7)	0
Blinding	119 (55.6)	35 (16.4)	60 (28.0)	109
Randomization	116 (54.7)	54 (25.5)	42 (19.8)	111
Sample size	94 (28.2)	19 (5.7)	210 (63.1)	0
Results
Primary endpoint	295 (88.6)	14 (4.2)	14 (4.2)	0
Harms/side effects	232 (69.7)	11 (3.3)	80 (24.0)	0
Participant flow	200 (60.1)	87 (26.1)	36 (10.8)	0
Deaths	190 (57.1)	2 (0.6)	131 (39.3)	0
Recruitment period	168 (50.5)	5 (1.5)	150 (45.0)	0
Severity of harms	153 (45.9)	16 (4.8)	154 (46.2)	0
Conclusion
Generalizability	300 (90.1)	17 (5.1)	6 (1.8)	0
Interpretation	272 (81.7)	43 (12.9)	8 (2.4)	0
Limitations	191 (57.4)	66 (19.8)	66 (19.8)	0
Other
Protocol	295 (88.6)	7 (2.1)	21 (6.3)	0
Funding	276 (82.9)	5 (1.5)	42 (12.6)	0
Registration	244 (73.3)	6 (1.8)	73 (21.9)	0

^aTen non-English-language publications were excluded from our analysis of completeness score. Percentages exclude trials with non-applicable reporting categories.

^bReporting categories modified for early-phase clinical trials from CONSORT (Moher et al., 2010, Schulz et al., 2010).